A phase II clinical trial of ROAR in 178 patients with BRAF V600E mutation, including 33 patients with advanced and refractory BC, evaluated the efficacy of the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, in the treatment of various types of tumors [44]. The gene discussed is BRAF; the disease is breast cancer.